Mirococept - Inflazyme Pharmaceuticals

Drug Profile

Mirococept - Inflazyme Pharmaceuticals

Alternative Names: APT 070; APT 070C

Latest Information Update: 06 Sep 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adprotech
  • Developer Adprotech; Inflazyme Pharmaceuticals
  • Class Anti-inflammatories; Antirheumatics; Recombinant proteins
  • Mechanism of Action Complement C1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Transplant rejection
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Inflammation; Inflammatory bowel diseases; Reperfusion injury; Rheumatoid arthritis; Shock; Transplant rejection

Most Recent Events

  • 12 Mar 2014 Discontinued - Phase-I for Shock in Canada (unspecified route) prior to 2014
  • 12 Mar 2014 Discontinued - Phase-II for Transplant rejection in United Kingdom (unspecified route) prior to 2014
  • 18 Jul 2005 Discontinued - Phase-II for Inflammation in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top